COMMUNIQUÉS West-GlobeNewswire

Novo Nordisk receives European Commission approval of Wegovy® pill as first oral GLP-1 for weight management in the EU; single, ready-to-use pen for higher dose 7.2 mg also approved
15/07/2026
First GLP-1 pill approved in the European Union for the treatment of obesity and overweight Only Wegovy ® pill demonstrates 17% * mean weight loss 1 and cardiovascular benefits Wegovy ® 7.2 mg injection in a single-dose [...]
IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2026
15/07/2026
Aggregated presentation by day and by market Weekly report on share repurchases from 6th to 10th July 2026 Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total [...]
Milestone Scientific Launches First Phase of AI Strategy with Pilot Debut of Milo, an AI-enabled Digital Engagement Platform, at ASPN 2026
15/07/2026
AI-powered Initiative Aims to Enhance Customer Engagement, Accelerate Commercial Execution and Support Long-Term Growth Visit booth #112 in the Sparkle Ballroom at Fontainebleau Miami Beach for a live demonstration of [...]
NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio
15/07/2026
Brazil patent complements U.S. patent portfolio for NCEL-101, strengthening global position in the type 1 diabetes market ZURICH, July 15, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (“NewcelX”; Nasdaq: NCEL), a clinical- [...]
Smith+Nephew introduces groundbreaking LYNX™ COBLATION™ Laryngeal Wand for ENT surgeons
15/07/2026
Delivering versatility for airway procedures in a single, streamlined surgical solution Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the commercial launch of its LYNX COBLATION [...]
VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027
15/07/2026
SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety [...]
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors
15/07/2026
ALLO-316 Achieved a 31% Confirmed Response Rate with the Recommended Phase 2 Regimen in Patients with Stage IV Renal Cell Carcinoma (RCC) with High CD70 Expression Single Dose of ALLO-316 Produced Durable Responses in [...]
New FDA-Cleared Single-Step Immunoblot IGeneX Tests Improve Early Detection of Lyme Disease, Study Finds
15/07/2026
Study published in Microbiology Spectrum shows single-step tests outperform conventional two-tier testing in early-stage Lyme disease MILPITAS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- IGeneX, Inc ., a specialty [...]
Cannara Reports Record Q3 Revenues and Continued Profitability Accompanied By Expanding National Distribution and Accelerated Capacity Expansion
15/07/2026
Delivered strong Q3 financial results: Generated $31.8 million in total net revenues, $13.4 million in gross profit before fair value adjustments, or 42% of revenues, $8.5 million in adjusted EBITDA 1 , and $5.7 million [...]
NOMAD Power Solutions Strengthens Subsidiary Executive Leadership
15/07/2026
Huda Almashhadany Joins Team as Chief of Product & VP of Operations, Company Names Brian Dockendorf as Director of Service Boca Raton, Fla., July 15, 2026 (GLOBE NEWSWIRE) -- NOMAD Power Solutions, Inc. (“NOMAD” or [...]
Attovia Therapeutics Appoints John W. Smither to Board of Directors
15/07/2026
Mr. Smither brings extensive public company board and audit committee experience in the biotechnology sector SAN CARLOS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company [...]
Sienna Announces July Dividend
15/07/2026
MARKHAM, Ontario, July 15, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “ Common Share ”) [...]
BillionToOne to Report Second Quarter 2026 Financial Results on August 5, 2026
15/07/2026
MENLO PARK, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, [...]
Biogen Appoints Michael J. Parini as Chief Legal Officer
15/07/2026
CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Michael J. Parini as Chief Legal Officer, effective August 3, 2026. Parini will serve as a member of [...]
BioAdaptives® Inc. Announces XcellaraHeart™, a Cardiovascular Wellness Formula Built on Xcellara’s Human-Clinical Data Demonstrating a 268.8% Increase in Circulating Stem/Progenitor-Type Cells
15/07/2026
The formula combines the Xcellara™ mobilization base with Tanshinone IIA, a Danshen-derived compound studied for its effects on the SDF-1α/CXCR4 signaling pathways involved in cellular trafficking and cardiovascular [...]
MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients
15/07/2026
LA JOLLA, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
Autonomix Medical Granted U.S. Patent for Overactive Bladder Diagnosis and Treatment Platform
15/07/2026
Newly Issued Patent Expands Company's Neural Sensing Technology Platform into Large Urology Market Affecting Approximately 37 Million Americans THE WOODLANDS, TX, July 15, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc [...]
SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome
15/07/2026
TEL AVIV, Israel, July 15, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage [...]
Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center
15/07/2026
- The ADMIRE study, by treating immunocompromised patients, builds on the momentum of Alpha Tau's ReSTART pivotal trial for recurrent cSCC, which recently completed patient enrollment, under which the Banner MD Anderson [...]

Pages